More than a billion people alive today carry at least one of a group of infections that rarely make headlines, rarely kill quickly, and rarely attract the research dollars their scale would seem to justify. This article sets out what the neglected tropical diseases actually are, how large their true burden is, why the economics and politics of medicine have left them under-resourced for decades, and what the record shows has genuinely worked to reduce that burden. The aim is not alarm but clarity: these are diseases of the poor, largely preventable and treatable, and understanding why they persist is the first step toward the kind of practical, family- and community-level responsibility that has already eliminated some of them almost entirely.
What Counts as a Neglected Tropical Disease
The World Health Organization currently designates 20 conditions as neglected tropical diseases, or NTDs. Most are caused by parasites and are the bread and butter of the field of parasitology: soil-transmitted helminths (roundworm, whipworm, hookworm), schistosomiasis, lymphatic filariasis, onchocerciasis (river blindness), Chagas disease, human African trypanosomiasis (sleeping sickness), leishmaniasis, and Guinea worm disease (dracunculiasis) among them. Others are bacterial, such as trachoma and leprosy (Hansen's disease), or viral, such as dengue. Snakebite envenoming was added to the list in 2017, reflecting the same underlying pattern: a condition that devastates poor rural populations while drawing little global attention or investment. What unites this otherwise diverse group is not the organism responsible but the epidemiology — these diseases cluster tightly among people living in poverty, in rural or peri-urban areas with limited sanitation, weak health infrastructure, and little political voice.
The Scale of the Burden: Common, Chronic, and Undercounted
The WHO's own figure, repeated in successive reports over the past decade, is that roughly 1.7 billion people require treatment or preventive care for at least one NTD in a given year — close to one in five people on Earth. Global Burden of Disease estimates, produced through the long-running collaborative modeling effort based at the Institute for Health Metrics and Evaluation in Seattle, consistently show that NTDs cause a comparatively modest number of deaths — on the order of a few hundred thousand per year across the whole category — but an outsized share of chronic disability. This is the central statistical trap of the field: because these diseases rarely kill outright, they are easy to underweight in health metrics built around mortality, even though they blind, disfigure, stunt, and impoverish on a massive scale. Trachoma remains a leading infectious cause of blindness worldwide. Lymphatic filariasis produces the grotesque swelling of limbs known as elephantiasis, a condition that carries not only physical disability but severe social stigma, often costing sufferers their livelihoods and marriage prospects. Leprosy, despite being fully curable with multidrug therapy since the 1980s, still generates new diagnoses each year, many with visible disability because affected people delayed seeking care out of fear of stigma. None of this shows up cleanly in a death count, which is precisely why the true burden of NTDs has historically been undercounted relative to headline killers like malaria, tuberculosis, and HIV.
Why They Stay Neglected: A Market That Doesn't Clear
The clearest documentation of the underlying problem is now more than two decades old. A widely cited analysis published in The Lancet in 2002 by Patrice Trouiller and colleagues, reviewing new drugs approved worldwide between 1975 and 1999, found that of roughly 1,400 new chemical entities brought to market, only a small handful — about 1 percent — were developed specifically for tropical diseases, despite those diseases accounting for a disproportionate share of global disease burden. This gap has a name in global health circles: the "10/90 gap," a term coined in the 1990s to describe the observation that only around 10 percent of global health research funding was directed at conditions responsible for roughly 90 percent of the world's disease burden. The reason is not mysterious or hidden; it is straightforward economics. Pharmaceutical research is expensive, and a company that develops a new drug needs to recoup that investment through sales. Populations most affected by onchocerciasis or Chagas disease are overwhelmingly rural, poor, and unable to pay market prices for treatment, so the commercial incentive to develop new drugs for them is weak compared to incentives for chronic diseases of wealthier populations. Ongoing tracking by the G-FINDER survey, run by the nonprofit Policy Cures Research, has for years shown that global funding for neglected disease research and development runs several billion dollars annually across all neglected conditions combined — a substantial sum in absolute terms, but small relative to the burden, and heavily concentrated on HIV, tuberculosis, and malaria rather than the parasitic NTDs proper. Political neglect compounds the market failure: because these diseases are chronic rather than epidemic, they generate little of the acute political pressure that drove, for instance, the rapid international response to Ebola outbreaks.
What Has Actually Worked
The record is not one of unrelieved failure, and the successes are instructive precisely because they show what breaks the pattern. Guinea worm disease offers the clearest case. In the mid-1980s, an estimated 3.5 million cases occurred annually across Africa and Asia. Through a sustained, low-technology campaign led by the Carter Center in partnership with national health ministries and the WHO — built almost entirely on water filtration, case containment, and community health education rather than a drug or vaccine, since none exists — human cases have fallen to fewer than twenty per year in recent reporting. It stands as one of the great near-eradications in the history of public health, achieved with unglamorous tools and patient, decades-long follow-through. Onchocerciasis and lymphatic filariasis programs tell a related story about the power of donated drugs distributed through community-based mass drug administration. Ivermectin, the drug at the center of river blindness control, was derived from a compound isolated from a soil bacterium, Streptomyces avermitilis, discovered by Satoshi Ōmura in Japan and developed with William Campbell at Merck — work recognized with the 2015 Nobel Prize in Physiology or Medicine. It is worth pausing on that origin: a molecule that has spared millions of people blindness and disfigurement came from an ordinary bacterium living in ordinary soil, a reminder that the created world continues to yield remedies to those who look for them. Since 1987, Merck's Mectizan Donation Program has supplied the drug free of charge for onchocerciasis and, in combination with other agents, for lymphatic filariasis, underpinning mass treatment across large parts of Africa and Latin America. Praziquantel, similarly donated for schistosomiasis control by Merck KGaA, has allowed school-based deworming campaigns to reach tens of millions of children annually. On the drug-development side proper, the nonprofit Drugs for Neglected Diseases initiative, founded in 2003 partly in response to the very market failure documented by Trouiller's group, developed fexinidazole, the first all-oral treatment for human African trypanosomiasis, validated in clinical trials conducted in the Democratic Republic of Congo and published in The Lancet around 2018, and approved by European regulators shortly after. It replaced a decades-old regimen that required hospitalization and carried meaningful toxicity. These examples share a pattern: progress came from public-private donation partnerships and nonprofit R&D models built specifically to work around, rather than depend on, ordinary market incentives.
Stewardship, Preparedness, and Honest Ethics
None of this diminishes the responsibility that sits closer to home. Many NTDs are diseases of water, sanitation, and hygiene as much as of pathogens — hookworm and schistosomiasis transmission depend on contaminated soil and water contact, trachoma spreads through poor facial hygiene and crowding. Families and communities that gain reliable clean water and basic sanitation see these diseases recede regardless of what any single drug accomplishes, which is why household-level investment in clean water remains one of the most cost-effective interventions in this entire field. Travelers, missionaries, and aid workers heading into endemic regions carry a personal duty to prepare properly — appropriate prophylaxis, footwear, and food and water precautions discussed with their own physician before departure, rather than assuming any single medication is a blanket shield. Mass drug administration campaigns, for their part, deserve a fair and honest accounting: they distribute medication to entire communities based on geographic risk rather than individual diagnosis, which is operationally necessary given the scale involved and has produced real, measurable reductions in disease, but it is also reasonable and legitimate for individuals to want to understand what they are being given and why, and to retain the ability to decline. Community-directed treatment programs generally rely on local health workers to explain the drugs and their purpose, and that practice of informed local engagement, rather than distant mandate, is worth preserving and strengthening as these programs continue.
Key takeaway: Neglected tropical diseases persist not because they are untreatable but because the people they affect have little market power and little political voice, and the record shows that sustained, locally engaged, low-cost interventions — clean water, donated medicines, and patient public-health follow-through — are what actually turn that record around.